Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$6.97M+72.3%-$8.37M+63.8%-$12.59M+46.3%-$20.34M+38.9%-$25.12M+29.7%
$197K-10.5%$202K+5.2%$200K0.0%$200K+100%$220K+29.4%
$11.97M+72.7%$14.31M+93.4%$12.24M+65.1%$8.23M+10.1%$6.93M+25.6%
-$24.65M-19.4%-$29.39M-104%-$20.65M+45.4%
$5.82M+886%$6.36M+8,731%$1.91M+577%$1M-3.7%$590K+239%
-$58.56M-67.6%-$4.74M-$51.7M-27.6%-$34.94M+65.8%
$1.2M-99.1%$2.31M-21.0%$2.56M+301%$1.95M-95.4%$136.56M+25.6%
-$82.01M-201%$70.92M+190%$16.08M+429%$80.97M+359%
-$30.47M-43.4%-$30.39M-96.8%-$21.24M+44.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Tarsus Pharmaceuticals, Inc. generate?
Tarsus Pharmaceuticals, Inc. (TARS) generated -$96.9M in operating cash flow over the trailing twelve months.
What is Tarsus Pharmaceuticals, Inc.'s free cash flow?
After $15.1M of capital expenditures, Tarsus Pharmaceuticals, Inc.'s free cash flow was -$104.4M over the trailing twelve months, down 2.6% year over year.
Where does Tarsus Pharmaceuticals, Inc.'s cash flow data come from?
Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.